SCIENCE & TECHNOLOGY: The Current Regulatory Landscape for Cardiac and Cardiovascular Safety Assessments—Part II

Posted 01 February 2011 | By Raymond A. Huml, MS, DVM, RAC J. Rick Turner 

Last month, in Part I of this two-part series, we provided an overview of the history of formalized cardiac safety assessment, a brief discussion of the dedicated study used to investigate a drug's propensity to increase the length of the QT/QTc interval, and an overview of the regulatory history of formalized cardiovascular safety assessment for antidiabetic drugs for Type 2 Diabetes Mellitus (T2DM).

Regulatory Focus newsletters

All the biggest regulatory news and happenings.